Moderna, Merck unveil mRNA-based cancer vaccine that cuts spread
Summary
Moderna and Merck announced that their personalized mRNA cancer vaccine, Intismeran, lowered the chance of melanoma returning and spreading in a late-stage trial. The vaccine trains the immune system to fight cancer by targeting mutations in tumor cells.Key Facts
- Intismeran is a personalized mRNA vaccine developed to treat melanoma.
- The vaccine showed success in reducing cancer recurrence and spread in a late-stage clinical trial.
- Results released are interim; detailed data will be shared at a future medical meeting.
- The vaccine was tested alongside Merck’s immunotherapy drug, Keytruda.
- If approved, it could help thousands of melanoma patients who had tumors removed by surgery.
- Melanoma affected over 1.5 million people in the US in 2023.
- The vaccine works by training the patient’s immune system to recognize and attack cancer cells.
- This is the first positive late-stage trial result for an mRNA vaccine against cancer.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
